Levels of Alternatively Spliced Tissue Factor in the Plasma of Patients with Pancreatic Cancer May Help Predict Aggressive Tumor Phenotype

Annals of Surgical Oncology

Volumn 22, Issue , 2015, Pages 1206-1211

  Unruh, Dusten ^a   Sagin, Farah ^a   Adam, Mariette ^b   Van Dreden, Patrick ^b   Woodhams, Barry J ^c   Hart, Kimberly ^a   Lindsell, Christopher J ^a   Ahmad, Syed A ^a   Bogdanov, Vladimir Y ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Diagnostica Stago   (France)

^c HaemaCon Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE; PACLITAXEL; THROMBOPLASTIN; TUMOR MARKER;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MIDDLE AGED; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PHENOTYPE; RETROSPECTIVE STUDY; THROMBOCYTE POOR PLASMA; ALTERNATIVE RNA SPLICING; BLOOD; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENETICS; LYMPH NODE METASTASIS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SECONDARY;

ACUTE CORONARY SYNDROME; ALTERNATIVE SPLICING; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; DIABETES MELLITUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; THROMBOPLASTIN;

EID: 84952871176     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4592-2     Document Type: Article

References (27)

1. Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood. 1998;91:4216–23.
2. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA. 1999;96:2311–5.
3. Egorina EM, Sovershaev M, Bjørkøy G, et al. Intracellular and surface distribution of monocyte tissue factor: application to intersubject variability. Arterioscler Thromb Vasc Biol. 2005;25:1493–8.
4. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003;9:458-62.
5. Bogdanov VY. Blood coagulation and alternative pre-mRNA splicing: an overview. Curr Mol Med. 2006;6:859–69.
6. Bogdanov VY, Kirk RI, Miller C, et al. Identification and characterization of murine alternatively spliced tissue factor. J Thromb Haemost. 2006;4:158–67.
7. Srinivasan R, Bogdanov VY. Alternatively spliced tissue factor: discovery, insights, clinical implications. Front Biosci (Landmark Ed). 2011;16:3061–71.
8. Zumbach M, Hofmann M, Borcea V, et al. Tissue factor antigen is elevated in patients with microvascular complications of diabetes mellitus. Exp Clin Endocrinol Diabetes. 1997;105:206–12.
9. Suefuji H, Ogawa H, Yasue H, et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J. 1997;134:253–9.
10. Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008;6:1983–5.
11. Soejima H, Ogawa H, Yasue H, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation. 1999;99:2908–13.
12. Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes. 2006;55:202–8.
13. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complicat. 2001;15:44–54.
14. Sambola A, Osende J, Hathcock J, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003;107:973–7.
15. Kocatürk B, Van den Berg YW, Tieken C, et al. Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner. Proc Natl Acad Sci USA. 2013;110:11517–22.
16. Unruh D, Turner K, Srinivasan R, et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer. 2014;134:9–20.
17. Van den Berg YW, Van den Hengel LG, Myers HR, et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci USA. 2009;106:19497–502.
18. Srinivasan R, Ozhegov E, Van den Berg YW, et al. Splice variants of tissue factor promote monocyte-endothelial interactions by triggering the expression of cell adhesion molecules via integrin-mediated signaling. J Thromb Haemost. 2011;9:2087–96.
19. Maithel SK, Maloney S, Winston C, et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2008;15:3512–20.
20. Key NS, Mackman N. Tissue factor and its measurement in whole blood, plasma, and microparticles. Semin Thromb Hemost. 2010;36:865–75.
21. Davila M, Robles-Carrillo L, Unruh D, et al. Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation? J Thromb Haemost. 2014;12:186–96.
22. Ryan RJ, Lindsell CJ, Hollander JE, et al. A multicenter randomized controlled trial comparing central laboratory and point-of-care cardiac marker testing strategies: the Disposition Impacted by Serial Point of Care Markers in Acute Coronary Syndromes (DISPO-ACS) trial. Ann Emerg Med. 2009;53:321–8.
23. Zawaski S, Hammes M, Balasubramanian V. Alternatively spliced human tissue factor and thrombotic tendencies in hemodialysis patients. Int J Nephrol Urol. 2010;2:193–99.
24. Kim YC, Kim HJ, Park JH, et al. Can preoperative CA 19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol. 2009;24:1869–75.
25. Ueno H, Kosuge T, Matsuyama Y, et al. A randomized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer. Br J Cancer. 2009;101:908–15.
26. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15–22.
27. Ugorski M, Laskowska A. Sialyl lewis: a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim Pol. 2002;49:303–11.